VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
IMAImageneBio Inc$5.43$61M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksIMAEarnings History

IMA logoImageneBio Inc (IMA) Earnings History

Net Loss

8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$45M
● Net Loss
TTM EPS (Diluted)
$-4.02
Per share, diluted
YoY EPS Growth
-954.9%
Declining
Net Margin
-5668.6%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-6056.4%
Gross Margin-29.1%
Return on Equity-35.0%
Return on Assets-30.8%
Record Annual Net Income-$17MFY2019
Record Quarterly EPS$0.08Q4 2021
Consecutive Profitable Years0years
Q1 2026
Net Income-$11M
EPS (Diluted)$-0.95
YoY Growth-954.9%Declining
QoQ Growth-53.7%Declining

Loading earnings history...

ImageneBio Inc (IMA) Earnings Overview

As of June 13, 2026, ImageneBio Inc (IMA) reported trailing twelve-month net income of -$45M, reflecting -954.9% year-over-year growth. The company earned $-4.02 per diluted share over the past four quarters, with a net profit margin of -5668.6%.

Looking at the long-term picture, IMA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$17M in fiscal 2019.

ImageneBio Inc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including SRZN (-$343M net income, -6960.8% margin), IMVT (-$506M net income), KYMR (-$315M net income, -794.4% margin), IMA has outperformed on profitability metrics. Compare IMA vs SRZN →

IMA Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
IMA logoIMACurrent
-$45M$-4.02-5668.6%-35.0%-954.9%—
SRZN logoSRZN
-$343M$-31.29-6960.8%--49.4%
IMVT logoIMVT
-$506M$-2.48--64.8%-1.5%
KYMR logoKYMR
-$315M$-3.23-794.4%-25.8%-23.8%
ARQT logoARQT
-$2M$-0.02-4.3%-9.3%+88.8%
PRTA logoPRTA
-$151M$-2.79-2520.6%-63.6%-99.6%
Best in group
Lowest in group

IMA Historical Earnings Data (2018–2025)

8 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$45M-24.0%-$48M$-10.76-5668.6%-6056.4%
2024-$37M+46.4%-$37M$-1.02-1044.8%-1057.1%
2023-$68M+0.9%-$75M$-1.63-744.2%-823.3%
2022-$69M-101.6%-$71M$-1.90-440.3%-454.0%
2021-$34M+22.9%-$34M$-0.95-110.1%-110.2%
2020-$44M-163.2%-$45M$-3.16-481.4%-484.2%
2019-$17M+58.8%-$18M$-0.47-122.3%-134.5%
2018-$41M--$41M$-1.14-4127.8%-4130.7%

Download Data

Export IMA earnings history in CSV or JSON format

Free sign-in required to download data

What if you invested $1,000 in IMA back in 2018?

Total return with dividends reinvested · 8+ years of data

Calculate Returns

How much would $100/month in IMA be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is IMA Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

IMA vs LLY — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.

Compare Now

IMA — Frequently Asked Questions

Quick answers to the most common questions about buying IMA stock.

What is IMA earnings per share (EPS)?

IMA trailing twelve-month (TTM) diluted EPS is $-4.02, reflecting -954.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.

What is ImageneBio Inc's net income?

ImageneBio Inc (IMA) trailing twelve-month net income is $-45M as of 2025. Earnings declined -954.9% year-over-year.

Is IMA profitable?

IMA is not currently profitable on a TTM basis, reporting a net loss of $-45M. Net margin is -5668.6%. Investors should monitor for a return to profitability.

What is IMA's earnings growth rate?

IMA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.

What are IMA's profit margins?

ImageneBio Inc net profit margin is -5668.6%, operating margin is -6056.4%, and gross margin is -29.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is -35.0%.

Is IMA growing earnings?

IMA earnings are declining — EPS fell -954.9% year-over-year. TTM net income dropped to $-45M. This contrasts with the 5-year CAGR of N/A.

What was IMA's best earnings year?

ImageneBio Inc's highest annual net income on record is $-17M, achieved in fiscal year 2019. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.

What were IMA's earnings last quarter?

IMA's most recent reported quarter was Q1 2026. Net income was $-11M with diluted EPS of $-0.95. For a full breakdown of all quarters, see the quarterly earnings table on this page.

IMA Earnings Over Time (2018–2025)

Net income & EPS — annual and quarterly view